Peter J. Schatz

A dimeric peptide with erythropoiesis-stimulating activity uniquely affects erythropoietin receptor ligation and cell surface expression

Rakesh Kumar Verma, Jennifer M. Green, Peter J. Schatz, Don M. Wojchowski

us (code pays fourni par la source)

RHEX, a novel regulator of human erythroid progenitor cell expansion and erythroblast development

Rakesh Kumar Verma, Su Su, Donald J. McCrann, Jennifer M. Green et autres

Ligation of erythropoietin (EPO) receptor (EPOR) JAK2 kinase complexes propagates signals within erythroid progenitor cells (EPCs) that are essential for red blood cell production. To reveal hypothesized novel EPOR/JAK2 targets, a phosphotyrosine (PY) phosphoproteomics approach was applied. Beyond known signal transduction factors, …

us (code pays fourni par la source)

RHEX, a novel regulator of human erythroid progenitor cell expansion and erythroblast development

Rakesh Kumar Verma, Su Su, Donald J. McCrann, Jennifer M. Green et autres

Ligation of erythropoietin (EPO) receptor (EPOR) JAK2 kinase complexes propagates signals within erythroid progenitor cells (EPCs) that are essential for red blood cell production. To reveal hypothesized novel EPOR/JAK2 targets, a phosphotyrosine (PY) phosphoproteomics approach was applied. Beyond known signal transduction factors, …

us (code pays fourni par la source)

Corrigendum to “Peginesatide and erythropoietin stimulate similar erythropoietin receptor–mediated signal transduction and gene induction events” [Experimental Hematology 40 (2012) 575–587]

Jennifer M. Green, Karen Leu, Angela Worth, Richard B. Mortensen et autres

us (code pays fourni par la source)

Anaemia in CKD 5D

A. Mikhail, Maria Kaplan, I. Macdougall, Rebecca J. Schmidt et autres

Introduction and Aims: Peginesatide is a once-monthly, peptide-based erythropoiesis-stimulating agent (ESA) approved in the US for treatment of anemia due to chronic kidney disease (CKD) in adult patients ( pts) on dialysis.Peginesatide demonstrated noninferiority to epoetin in maintaining hemoglobin (Hb) in hemodialysis …

de, se, fr, us, jp, hr, ro, ch, gb, it (code pays fourni par la source)

The Erythropoiesis Stimulating Agent Omontys/Peginesatide up-Modulates Erythroid Progenitor Formation, and Cell Surface Erythropoietin Receptor Levels.

Rakesh Kumar Verma, Jennifer M. Green, Karen Leu, Richard B. Mortensen et autres

Abstract Abstract 2089 Peginesatide is a peptide-based erythropoietin receptor (EPOR) agonist with recent FDA approval for treating the anemia of chronic kidney disease among adult dialysis patients. Although peginesatide exhibits a 47.9h half-life when given IV in dialysis patients, it is administered …

us (code pays fourni par la source)

Peginesatide and erythropoietin stimulate similar erythropoietin receptor–mediated signal transduction and gene induction events

Jennifer M. Green, Karen Leu, Angela Worth, Richard B. Mortensen et autres

us (code pays fourni par la source)

Dynamic Ligand Modulation of EPO Receptor Pools, and Dysregulation by Polycythemia-Associated EPOR Alleles

Seema Singh, Rakesh Kumar Verma, Anamika Pradeep, Karen Leu et autres

Erythropoietin (EPO) and its cell surface receptor (EPOR) are essential for erythropoiesis; can modulate non-erythroid target tissues; and have been reported to affect the progression of certain cancers. Basic studies of EPOR expression and trafficking, however, have been hindered by low-level EPOR …

us (code pays fourni par la source)

“RHEX-26”, a Novel EPO/EPOR-Regulated Mediator of Human Erythroid Progenitor Cell Expansion

Rakesh Kumar Verma, Karen Leu, Peter R. Young, Peter J. Schatz et autres

Abstract Abstract 682 Erythropoietin (EPO) and its receptor (EPOR) serve well as an informative paradigm for understanding hematopoietic growth factor effects and receptor action mechanisms. Recently, interest in EPO/EPOR investigations has been heightened based on the clinical emergence of novel EPO mimetics, …

us (code pays fourni par la source)

Dose-finding Study of Peginesatide for Anemia Correction in Chronic Kidney Disease Patients

Iain C. Macdougall, Andrzej Więcek, Beatriz Tucker, Magdi M. Yaqoob et autres

BACKGROUND AND OBJECTIVES: Peginesatide is a synthetic, PEGylated, investigational, peptide-based erythropoiesis-stimulating agent. We report the first assessment of its efficacy and safety in correcting renal anemia in a population of 139 nondialysis chronic kidney disease patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Chronic …

gb, pl, us (code pays fourni par la source)

Methods for detection and confirmation of Hematide™/peginesatide in anti-doping samples

Nicolas Leuenberger, Jérémy Saugy, Richard B. Mortensen, Peter J. Schatz et autres

ch, us (code pays fourni par la source)

Genotoxic assessment and toxicity evaluation of peginesatide in CByB6F1 hybrid mice

Kathryn W. Woodburn, Peter J. Schatz, Susan D. Wilson, K L Fong et autres

Peginesatide is a PEGylated, investigational, peptide-based erythropoiesis-stimulating agent (ESA) that was designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis. Clinical use of peginesatide is anticipated to result in chronic dosing in chronic kidney disease (CKD) patients, and …

us (code pays fourni par la source)